t cell depleted hematopoietic stem cells
Cell therapyexperimental
Clinical trial activity
10 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
10
Phase 3
2
Phase 4
0
Earliest trial started Aug 1, 2001 (NCT00023192)
Timeline
Indications
Studied for
- Anemia, Aplastic · Phase 2
- Bone Marrow Failure Disorders · Phase 2
- Granulomatous Disease, Chronic · Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 1/Phase 2
- Leukemia · Phase 2
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Leukemia, Myelomonocytic, Juvenile · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 3
- Neoplasm Metastasis · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Sarcoma, Myeloid · Phase 2
Mechanism of action
- LymphocytesTissue restoration
tissue restoration - lymphocytes
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- donor tcr alpha/beta-depleted cells
- donor tcr α/β-depleted cells
- haploidentical transplantation of t-cell depleted graft
- t-cell depleted, cd34+ hematopoietic stem cells
- t-cell depleted hematapoietic stem cells
- t cell depleted hematopoietic stem cells
- t-cell depleted peripheral blood stem cell
- t-cell depleted peripheral blood stem cells
- tcralphabeta-depleted hematopoietic stem cell
- tcrαβ-depleted hematopoietic stem cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04558736 | Phase 2 | Nov 30, 2020 | St. Jude Children's Hospital |
| NCT02999854 | Phase 3 | May 1, 2017 | Kiadis Pharma, University of Montreal |
| NCT02014506 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | University of Ulsan |
| NCT02259348 | Phase 2 | Oct 1, 2014 | St. Jude Children's Hospital |
| NCT01370213 | Phase 2 | Sep 1, 2011 | University of Minnesota |
| NCT01119066 | Phase 2 | May 1, 2010 | Cornell University |
| NCT01025778 | Phase 2 | Dec 1, 2009 | Lund University |
| NCT00416884 | Phase 2 | May 1, 2003 | National Cancer Institute (NCI), Oregon Health and Science University |
| NCT00113646 | Phase 2 | Nov 1, 2002 | Harvard University |
| NCT00023192 | Phase 3 | Aug 1, 2001 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| St. Jude Children's Hospital | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Kiadis Pharma | For profit | 1 | 1 | 1 | 2017 |
| Lund University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2001 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2017 |
11 organizations
Page 1 / 1